(2S)-N-[2-[(benzyloxy)methyl]-7-(2-chlorophenyl)-6-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide | 1044588-23-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2S)-N-[2-[(benzyloxy)methyl]-7-(2-chlorophenyl)-6-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide
• 英文别名: (2S)-N-[7-(2-chlorophenyl)-6-(4-chlorophenyl)-2-methyl-2-(phenylmethoxymethyl)-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide
• CAS: 1044588-23-9
• 化学式: C₃₂H₃₀Cl₂N₂O₄
• 分子量: 577.507
• InChiKey: DNSZIYGYCAEKKO-LIEYLQLASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S)-N-[2-[(benzyloxy)methyl]-7-(2-chlorophenyl)-6-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide 生成 (2S)-N-[(2S,4S)-2-[(benzyloxy)methyl]-7-(2-chlorophenyl)-6-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide 、 (2S)-N-[(2S,4R)-2-[(benzyloxy)methyl]-7-(2-chlorophenyl)-6-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide 、 (2S)-N-[(2R,4S)-2-[(benzyloxy)methyl]-7-(2-chlorophenyl)-6-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide 、 (2S)-N-[(2R,4R)-2-[(benzyloxy)methyl]-7-(2-chlorophenyl)-6-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide
  参考文献：
  名称：

  WO2008/94476

  摘要：

  公开号：

文献信息

• Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
  申请人：Debenham John S.

  公开号：US20080207666A1

  公开（公告）日：2008-08-28

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，并可用于治疗、预防和抑制CB1受体介导的疾病。本发明的化合物可用作中枢作用药物，治疗精神病、记忆障碍、认知障碍、阿尔茨海默病、偏头痛、神经病、神经炎性疾病，包括多发性硬化症和吉兰-巴雷综合征，以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、亨廷顿病运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖或进食障碍，以及哮喘、便秘、慢性肠假性梗阻、肝硬化、非酒精性脂肪肝病（NAFLD）、非酒精性脂肪性肝炎（NASH）和促进清醒。
• US7999107B2
  申请人：——

  公开号：US7999107B2

  公开（公告）日：2011-08-16